Gene · 607
BCL9: BCL9 transcription coactivator
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BCL9: BCL9 transcription coactivator. Genes, record 607. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/607
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00512 | B-cell CLL/lymphoma 9 protein | 1,426 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents20
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 38673 | O00512 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 895 | O00512 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 631 | O00512 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 631 | O00512 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 895 | O00512 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 8475 | O00512 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 8475 | O00512 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 111446 | O00512 | Espacenet |
| US 10828377 B2 | 2020-11-10 | 6 | O00512 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 219108 | O00512 | Espacenet |
1 to 10 of 20
See all 20 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants767
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BCL9 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 9 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 7 | 2025 |
| R35CA197695 | Translating genomic discoveries to improved outcomes for high risk acute leukemia | 6 | 2025 |
| P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 5 | 2025 |
| U10CA180886 | COG NCTN Network Group Operations Center - Year 11 STAR Act MCI and PEC Supplement | 4 | 2025 |
| U10CA180899 | Children's Oncology Group Statistics and Data Center | 4 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 3 | 2025 |
1 to 10 of 767Source NIH's project files
See all 767 nih grantsPapers1,232
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
ZD-4009, a novel B-cell lymphoma 9 inhibitor, is associated with ameliorated pulmonary fibrosis and reduced hypoxia-inducible factor 1α-mediated glycolysis and transforming growth factor-β/SMAD signaling. | Mol Pharmacol | 2026 | 42721930 | PubTator, text mining | PubMed |
| BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage-fibroblast interactions to attenuate pulmonary fibrosis. | Signal Transduct Target Ther | 2026 | 42543261 | PubTator, text mining | PubMed |
| [Clinical analysis of 9 children of B-cell acute lymphoblastic leukemia with MEF2D gene rearrangement]. | Zhonghua Er Ke Za Zhi | 2026 | 42527140 | PubTator, text mining | PubMed |
| Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling. | Acta Pharmacol Sin | 2026 | 42366227 | PubTator, text mining | PubMed |
| ZW4864-mediated inhibition of the β-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer. | Mol Oncol | 2026 | 42316797 | PubTator, text mining | PubMed |
| Determination of copy number variations and affected gene networks in breast cancer. | Biomed Rep | 2026 | 42221547 | PubTator, text mining | PubMed |
| Disruption of BCL9-β-catenin interaction by de novo designed miniproteins inhibits oncogenic signaling. | Int J Biol Macromol | 2026 | 42190771 | PubTator, text mining | PubMed |
| Probiotic-derived EPS-ZnO nanoparticles: therapeutic potential in colorectal cancer gene regulation. | Cancer Cell Int | 2026 | 42092948 | PubTator, text mining | PubMed |
| Erratum for the Research Article "Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling". | Sci Transl Med | 2026 | 42054497 | PubTator, text mining | PubMed |
| Therapeutic Activities of Multipotent Stromal Cells for Islet Regeneration. | Cells | 2026 | 41892279 | PubTator, text mining | PubMed |
1 to 10 of 1,232
See all 1,232 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/607
GET https://conductscience.org/api/genes/v1/607/patents